CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture

Angelo Michael Demarzo, Chad Bradshaw, Jurgita Sauvageot, Jonathan Ira Epstein, Gary J. Miller

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Altered expression of CD44 has been implicated in tumor progression and metastasis in multiple neoplasms. METHODS. CD44 expression in archival tissues of prostate carcinoma was examined by immunohistochemistry with monoclonal antibodies against core CD44 and the RNA splice variant CD44v6 (v6). RESULTS. Core CD44 expression was reduced in the majority of primary neoplastic foci (n = 94) and loss of expression correlated with increasing Gleason grade. Staining for v6 was absent in most carcinomas and metastases. Expression of core CD44 in pelvic lymph node (n = 27) and bone metastases (n = 21) was significantly reduced. In addition, CD44 expression correlated with cytoarchitecture. Tall columnar tumor cells typically stained positively, yet more rounded cells forming cribriform structures or nests showed reduced expression. All cases of high-grade prostatic intraepithelial neoplasia were positive for core CD44 yet, there was decreased expression in cribriform and micropapillary variants. CONCLUSIONS. The majority of clinically relevant human prostatic carcinomas and metastases downregulate expression of CD44. Additional studies to determine whether CD44 cell surface expression relates to clinical outcome independent of other established clinicopathologic risk factors are warranted.

Original languageEnglish (US)
Pages (from-to)162-168
Number of pages7
JournalProstate
Volume34
Issue number3
DOIs
StatePublished - Feb 15 1998

Fingerprint

Down-Regulation
Neoplasm Metastasis
Carcinoma
Prostatic Intraepithelial Neoplasia
Neoplasms
Prostate
Lymph Nodes
Immunohistochemistry
Monoclonal Antibodies
RNA
Staining and Labeling
Bone and Bones

Keywords

  • Antigens, CD44
  • Metastasis
  • Prostatic intraepithelial neoplasia
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

CD44 and CD44v6 downregulation in clinical prostatic carcinoma : Relation to Gleason grade and cytoarchitecture. / Demarzo, Angelo Michael; Bradshaw, Chad; Sauvageot, Jurgita; Epstein, Jonathan Ira; Miller, Gary J.

In: Prostate, Vol. 34, No. 3, 15.02.1998, p. 162-168.

Research output: Contribution to journalArticle

@article{ec808698bd4d4ba699b538a9808873c1,
title = "CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture",
abstract = "BACKGROUND. Altered expression of CD44 has been implicated in tumor progression and metastasis in multiple neoplasms. METHODS. CD44 expression in archival tissues of prostate carcinoma was examined by immunohistochemistry with monoclonal antibodies against core CD44 and the RNA splice variant CD44v6 (v6). RESULTS. Core CD44 expression was reduced in the majority of primary neoplastic foci (n = 94) and loss of expression correlated with increasing Gleason grade. Staining for v6 was absent in most carcinomas and metastases. Expression of core CD44 in pelvic lymph node (n = 27) and bone metastases (n = 21) was significantly reduced. In addition, CD44 expression correlated with cytoarchitecture. Tall columnar tumor cells typically stained positively, yet more rounded cells forming cribriform structures or nests showed reduced expression. All cases of high-grade prostatic intraepithelial neoplasia were positive for core CD44 yet, there was decreased expression in cribriform and micropapillary variants. CONCLUSIONS. The majority of clinically relevant human prostatic carcinomas and metastases downregulate expression of CD44. Additional studies to determine whether CD44 cell surface expression relates to clinical outcome independent of other established clinicopathologic risk factors are warranted.",
keywords = "Antigens, CD44, Metastasis, Prostatic intraepithelial neoplasia, Prostatic neoplasms",
author = "Demarzo, {Angelo Michael} and Chad Bradshaw and Jurgita Sauvageot and Epstein, {Jonathan Ira} and Miller, {Gary J.}",
year = "1998",
month = "2",
day = "15",
doi = "10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K",
language = "English (US)",
volume = "34",
pages = "162--168",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - CD44 and CD44v6 downregulation in clinical prostatic carcinoma

T2 - Relation to Gleason grade and cytoarchitecture

AU - Demarzo, Angelo Michael

AU - Bradshaw, Chad

AU - Sauvageot, Jurgita

AU - Epstein, Jonathan Ira

AU - Miller, Gary J.

PY - 1998/2/15

Y1 - 1998/2/15

N2 - BACKGROUND. Altered expression of CD44 has been implicated in tumor progression and metastasis in multiple neoplasms. METHODS. CD44 expression in archival tissues of prostate carcinoma was examined by immunohistochemistry with monoclonal antibodies against core CD44 and the RNA splice variant CD44v6 (v6). RESULTS. Core CD44 expression was reduced in the majority of primary neoplastic foci (n = 94) and loss of expression correlated with increasing Gleason grade. Staining for v6 was absent in most carcinomas and metastases. Expression of core CD44 in pelvic lymph node (n = 27) and bone metastases (n = 21) was significantly reduced. In addition, CD44 expression correlated with cytoarchitecture. Tall columnar tumor cells typically stained positively, yet more rounded cells forming cribriform structures or nests showed reduced expression. All cases of high-grade prostatic intraepithelial neoplasia were positive for core CD44 yet, there was decreased expression in cribriform and micropapillary variants. CONCLUSIONS. The majority of clinically relevant human prostatic carcinomas and metastases downregulate expression of CD44. Additional studies to determine whether CD44 cell surface expression relates to clinical outcome independent of other established clinicopathologic risk factors are warranted.

AB - BACKGROUND. Altered expression of CD44 has been implicated in tumor progression and metastasis in multiple neoplasms. METHODS. CD44 expression in archival tissues of prostate carcinoma was examined by immunohistochemistry with monoclonal antibodies against core CD44 and the RNA splice variant CD44v6 (v6). RESULTS. Core CD44 expression was reduced in the majority of primary neoplastic foci (n = 94) and loss of expression correlated with increasing Gleason grade. Staining for v6 was absent in most carcinomas and metastases. Expression of core CD44 in pelvic lymph node (n = 27) and bone metastases (n = 21) was significantly reduced. In addition, CD44 expression correlated with cytoarchitecture. Tall columnar tumor cells typically stained positively, yet more rounded cells forming cribriform structures or nests showed reduced expression. All cases of high-grade prostatic intraepithelial neoplasia were positive for core CD44 yet, there was decreased expression in cribriform and micropapillary variants. CONCLUSIONS. The majority of clinically relevant human prostatic carcinomas and metastases downregulate expression of CD44. Additional studies to determine whether CD44 cell surface expression relates to clinical outcome independent of other established clinicopathologic risk factors are warranted.

KW - Antigens, CD44

KW - Metastasis

KW - Prostatic intraepithelial neoplasia

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0031981414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031981414&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K

DO - 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K

M3 - Article

C2 - 9492843

AN - SCOPUS:0031981414

VL - 34

SP - 162

EP - 168

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -